Concepedia

Author

B. Weber

Délégation Centre-EstORCID

Also Known As

B WEBER, B Weber, B. E. Weber, B. WEBER, B. Weber, Beatrice E. Weber, Beatrice Weber, Bryce Weber, Béatrice Weber, C McCoss

151

Publications

8.4K

Citations

37

H-Index

89

Concepts

All Affiliations

Délégation Centre-EstUniversité Paris CitéCentre Léon BérardHôtel-Dieu de ParisTechnische Universität Dresden
BW

About

B. Weber is an author at Délégation Centre-Est specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

24

41

4.4K

2

Health Sciences

6

6

341

3

Natural Sciences

3

3

79

4

Engineering

2

2

50

5

Business

1

1

14

B. Weber

×

67

Publications

7.8K

Citations

35

H-Index

YearCitations

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle,

The Lancet Oncology

2017

1.8K

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Éric Pujade-Lauraine, Felix Hilpert, B. Weber,

Journal of Clinical Oncology

2014

1.6K

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann,

The Lancet Oncology

2021

391

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros,

The Lancet Oncology

2014

386

Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study

Gilles Freyer, J.-F. Geay, Sandrine Touzet,

Annals of Oncology

2005

340

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

Jacobus Pfisterer, B. Weber, Rainer Kimmig,

JNCI Journal of the National Cancer Institute

2006

208

Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens

Andreas du Bois, B. Weber, Justine Rochon,

Journal of Clinical Oncology

2006

196

HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients

Marianne Tuefferd, Jérôme Couturier, Frédérique Penault–Llorca,

PLoS ONE

2007

185

AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

Éric Pujade-Lauraine, Felix Hilpert, B. Weber,

Journal of Clinical Oncology

2012

136

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

Bruno Coudert, Rémy Largillier, Laurent Arnould,

Journal of Clinical Oncology

2007

132

Page 1